|Bid||0.00 x 1400|
|Ask||0.00 x 1000|
|Day's Range||21.75 - 22.62|
|52 Week Range||19.20 - 35.37|
|Beta (3Y Monthly)||1.30|
|PE Ratio (TTM)||54.31|
|Earnings Date||May 6, 2019 - May 10, 2019|
|Forward Dividend & Yield||0.24 (0.94%)|
|1y Target Est||29.50|
AUSTIN, Texas , April 18, 2019 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the first quarter ended March 31, 2019 on Monday, May 6, 2019 . A press ...
Widening pharmacy network, healthy prescription volumes along with contributions from Rite Aid are expected to contribute to Walgreens Boots' (WBA) top line in the fiscal second quarter.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! A large part of investment returns can be generated by dividend-paying stock given their role in compounding returns over tim...
Luminex (LMNX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AUSTIN, Texas , March 5, 2019 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the Barclays Global Healthcare Conference to be held March 12-14, 2019 , ...
Luminex Corp develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. Its products include MAGPIX, Luminex 100/200, and FLEXMAP 3D. The dividend yield of Luminex Corp stocks is 0.91%.
Amidst the usual venture capital rounds, a pair of multimillion-dollar military contracts were awarded to Austin businesses.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Anyone researching Luminex Corporation (NASDAQ:LMNX) might want to consider theRead More...
NEW YORK, Feb. 19, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CET, February 19, 2019 - MDxHealth SA (Euronext:MDXH.BR), today announced the appointment of Michael K. McGarrity to the position of Chief Executive Officer and member of the Board of Directors effective February 19, 2019. Mr. McGarrity has more than 25 years of experience in the healthcare industry with a unique combination of device, diagnostics and biotechnology experience. Michael was most recently the CEO of Sterilis Medical.
AUSTIN, Texas , Feb. 8, 2019 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company"), today announced that its board of directors declared a cash dividend for the first quarter of ...
Luminex (LMNX) delivered earnings and revenue surprises of -66.67% and 2.63%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
The Austin, Texas-based company said it had a loss of 5 cents per share. Earnings, adjusted for costs related to mergers and acquisitions and pretax expenses, were 4 cents per share. The results did not ...
AUSTIN, Texas , Feb. 4, 2019 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the fourth quarter and full-year 2018. Financial and operating highlights for the quarter ...
Luminex (LMNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be remiss not to mention that insider sales have Read More...
Luminex (LMNX) gains from strength in the Aries platform. However, cutthroat competition in the life sciences industry is worrisome.
AUSTIN, Texas, Jan. 7, 2019 /PRNewswire/ -- Luminex Corporation (LMNX) today announced that it expects its revenues in the fourth quarter of 2018 to be approximately $81 million and to exceed $315 million for the full- year ended 2018, near the top of the previously communicated guidance range of $310 to $316 million. Total MDx revenue of approximately $164 million, up 1% over the full year 2017, inclusive of the departure of approximately $13 million of LabCorp non-CF revenue. Total MDx revenue was up by approximately 13%, excluding the departure of LabCorp.